Last First MI Suffix Degrees
E-mail: _________________________ Phone: _______________________ Fax: ______________________
Title:____________________________ Department: __________________ Institution: _______________
(if applicable) Name Email Phone
Please describe your cancer-related primary research interest and any other research interests related to cancer. Attach additional pages as necessary:
List "key" search words related to your primary research area:
1 – Cancer Biology
2 – Hematologic Malignancies
3 – Solid Tumors Studies
4 – Prevention, Control, and Population
Please return application, NIH-formatted biographical sketch, NIH other support, and your CV to:
OHSU Knight Cancer Institute
3181 SW Sam Jackson Park Rd., CR 145
Portland, OR 97239-3098
The mission of the Knight Cancer Institute (institute) at Oregon Health & Science University (OHSU) is to reduce the impact that cancer has on all of our lives by providing world class, patient focused, comprehensive and coordinated clinical care; conducting groundbreaking research; and training the next generation of oncology researchers and clinicians. To reduce cancer incidence, morbidity and mortality, we must bring together the energy and abilities of the talented and diverse cancer researchers and clinicians at OHSU and its affiliates.
The Knight Cancer Institute aims to ensure that no person will have to travel out of our region for world-class care; maintain our leadership position in personalized cancer medicine; and reduce Oregon’s death rate from cancer to the lowest in the nation.
The OHSU Knight Cancer Institute is:
a matrix cancer center at OHSU in Portland, Oregon
the only National Cancer Institute (NCI) designated cancer center between Sacramento and Seattle
one of the 63 NCI cancer centers nationwide
The institute has been an NCI-designated cancer center for 14 years and is comprised of four scientific programs and eight core facilities. Among its more than 150 members are basic, clinical, and population scientists who collaborate on ground-breaking translational research. The institute is directed by Brian Druker, MD. Dr. Druker, member of the National Academy of Sciences and recipient of both the Charles F. Kettering Prize and the Keio Medical Science Prize, has a top priority: recruit and retain outstanding cancer researchers and clinicians to the institute, equip them with the best resources, and support their efforts to target the underlying causes of cancer.
The OHSU Knight Cancer Institute recently received a $100 million gift from Philip H. and Penny Knight. The Nike founder's gift – the largest in the history of OHSU – is transformative as far as its impact on allowing the cancer institute to achieve its ambitious goals.
The institute welcomes applications for membership from individuals who have major cancer related efforts in research, patient care, or education. The institute’s research programs must fulfill certain NCI criteria to receive approval for funding. They include: (a) evidence that membership leads to intra- and inter-programmatic collaboration, (b) evidence of regular participation of members in program-related meetings, (c) a significant publication record of program members, and (d) evidence that the research activities of members are either cancer focused or relevant to the cancer problem. Physician members should be board certified if specialty (and subspecialty) boards exist in their fields.
Eligible for membership are physicians involved in clinical or basic research, research scientists, and education/outreach and prevention control specialists whose primary objective is to organize and help accomplish the basic concept, mission, and goals of the institute. The institute oversees all cancer related-activities on campus to: (1) encourage multidisciplinary patient care in order to improve outcomes in patients with cancer, (2) maximize OHSU’s cancer-related research potential; and (3) directly provide and indirectly enhance education about cancer in our institution and in our communities. By providing administrative and program support, laboratory space, support for core laboratory facilities, pilot projects, and support for new faculty, the Cancer Institute facilitates collaborative interactions across departmental lines in a way that that enhances patient care, research, and education.
Institute membership is separated into four research programs. Each of these programs is broken down into work (focus) groups. The programs and their work groups are detailed below:
Program 1: Cancer Biology
Co-Leaders: Matt Thayer, PhD and Rosalie Sears, PhD
The Cancer Biology program constitutes the foundation of basic science research of the institute. The overall goal of the Cancer Biology Program is to investigate the underlying cellular and molecular mechanisms involved in the development of cancer and in the regulation of both normal and abnormal cell growth. The scientific thrust of the program is in two related areas of investigation: Carcinogenesis/Genetic Instability and Signal Transduction. Members of the Carcinogenesis/Genetic Instability group focus their studies around cell cycle control, the regulation of apoptosis, and the relationship of these events to the development of genetic instability and cancer. The members of the Signal Transduction group focus their studies around general signaling mechanisms of relevance to regulation of normal and cancer cell growth: the integrated function of growth factors and their receptors, kinase-mediated signaling phenomena, and the regulation of transcription that lies downstream of the aforementioned events. Because of the seamless nature of cellular regulation that is relevant to the cancer problem, there is a great deal of overlap between the research interests of the two groups.
Program 2: Hematologic Malignancies
Interim Leader: Mike Deininger, MD, PhD
The main goal of the Hematologic Malignancies Program is to develop novel molecularly-targeted approaches for the treatment and prevention of hematopoietic malignancies based on an understanding of the molecular pathogenesis of these disorders. There are three focus groups within the Hematologic Malignancies Program: Hematopoiesis, Molecular Leukemogenesis/ Lymphomagenesis, and HIV/AIDS. Members of the Hematopoiesis focus group study the events that control proliferation, survival, and differentiation of hematopoietic stem cells and investigate how hematologic malignancies evolve from molecular disorder of these cells. This also includes studies of how perturbations of the hematopoietic microenvironment, genetic instability, or stem cell damage can lead to hematologic malignancies. The Molecular Leukemogenesis/Lymphomagenesis focus group seeks to define and understand the molecular defects that cause leukemias and lymphomas. By understanding precise causal mechanisms, therapeutic agents can be developed that specifically target the abnormality. This approach has been validated by this program’s discovery and development of imatinib as a molecularly-targeted agent for CML. The HIV/AIDS focus group includes investigators with interests in the structure and function of HIV, with specific emphasis on the mechanism of viral infectivity, tissue tropism, and targets of HIV for therapy, along with the mechanism of bone marrow suppression and predisposition to malignancy caused by HIV infection and the molecular pathogenesis of Kaposi sarcoma. The Hematologic Malignancies Program has provided a successful framework that promotes interactions between basic scientists involved in hematological research and related diseases and the clinicians treating these disorders. It also emphasizes translating laboratory findings into the clinic and performing scientific studies in association with clinical trials to assist in patient selection, understanding responses, and optimizing therapy.
Program 3: Solid Tumors
Co-Leaders: Molly Kulesz-Martin, PhD and Alan Sandler, MD
The primary goals of the Solid Tumors Program are to develop novel molecularly-targeted approaches for prevention and treatment of malignancies arising from mucocutaneous, urogenital, and gut epithelia and mesenchymal tissues and to design and conduct translational clinical trials based on findings in basic and/or population research studies. The Solid Tumors Program researchers apply cellular, molecular biological, and genetic techniques to advance understanding of molecular pathogenesis. Research in this program involves studies of normal and malignant cells, as well as inherited diseases that predispose to the development of epithelial malignancies by combined mechanisms of genetic instability and microenvironmental perturbations. There are three focus groups within this program: Gastrointestinal Malignancies, Prostate Cancer, and Other Solid Tumors. The Gastrointestinal Malignancies group focuses on new methods for screening, diagnosis, prevention, and therapy of esophageal, pancreatic, and colorectal malignancies, as well as characterizing mechanisms of resistance and developing new therapies for patients with Gastrointestinal Stromal Tumors (GIST). The GI focus group meets weekly. The Prostate Cancer group was formed approximately five years ago, and has developed a horizontally integrated, multidepartmental, and translational group of scientists who conduct integrated research in cancer biology, translational, clinical, and population science in ways that capitalize on the organizational structure and shared resources of the OHSU Cancer Institute. This focus group meets weekly and is highly interactive. The Other Solid Tumors group encompasses a variety of cancer types, particularly skin malignancies, breast cancer, gynecologic malignancies, and bone and soft tissue sarcomas. Members of this group meet at least once weekly, having initiated a highly successful campus-wide carcinogenesis journal club. The program provides a successful framework that promotes interactions between basic scientists involved in research on epithelial cell survival, differentiation, and clonal evolution and clinicians treating these disorders who also develop translational clinical trials.
Program 4: Cancer Prevention, Control, and Population Studies
Co-Leaders: Patty Carney, PhD and Jeffery Fellows PhD
The Cancer Prevention, Control, and Population Studies Program aims to reduce cancer incidence, morbidity, and mortality by identifying controllable risk factors, special high-risk target groups, and molecular markers of risk and tumor aggressiveness. Using such knowledge, the program members seek to develop and test interventional strategies, and, by the translation of such knowledge into practice, to establish new standards of care. A monthly Cancer Prevention and Control Seminar Series serves to enhance collaborations internally and interprogrammatically, with a particular emphasis on aiding junior investigators and trainees. This program comprises three focus areas: (1) Survivorship and Symptom Management, (2) Surveillance and Epidemiology, and (3) Underserved Populations. The Survivorship and Symptom Management group is focused on documenting and decreasing the short and long-term side effects of cancer and its treatment. This focus group studies secondary and tertiary prevention in cancer patients and survivors. The Epidemiology and Surveillance group uses the traditional tools of epidemiology to study causes of cancer: the work of this group aims to lead to interventions directed toward primary cancer prevention. The third group is focused on Underserved Populations. The institute has a particular connection to the Native American population in the Pacific Northwest. Each year numerous Native American researchers come to OHSU to be trained in cancer prevention and control research. Rural Oregonians are also a special population that must navigate particular barriers to cancer treatment and services; the program is involved in designing outreach programs to these groups. Program members in all three focus groups work with researchers in the other institute programs to accomplish their work.
For Our Members
The Knight Cancer Institute provides shared resources that give ready access to state-of-the-art technologies and also provides developmental support for new faculty startups and pilot projects.
Biostatistics Shared Resource
Director: Motomi Mori, PhD
The primary goal of the Biostatistics Shared Resource (BSR) is to provide biostatistics support to basic scientists, clinical researchers, and population scientists who are conducting cancer research at OHSU. The BSR strives to enhance scientific quality of research through tailored professional consultation and collaboration at all phases of cancer research. The BSR encourages cancer researchers to seek biostatistics consultation at the earliest stage possible and to work with a biostatistician as a collaborator and co-investigator.
Grant submission and clinical protocol development
Study and experimental design
Sample size and power analysis
Statistical analysis plan
Development and implementation of statistical protocols for high-throughput cores
Institutional clinical research support, including scientific review and data monitoring
Manuscript preparation and review*
Training and education (e.g., software training)*
*denotes services that are performed on a fee-for-service basis.
Clinical Research Management Shared Resource
Director: Bashi Ratterree, BSN, CCRP
To support Knight Cancer Institute investigators in conducting basic, clinical and epidemiological research aimed at improving the lives of people and families with cancer by applying innovative strategies for cancer prevention, cancer treatment and support of cancer survivors
This resource provides centralized services for the initiation, conduct and quality assurance of cancer related clinical trials. The process of initiating trials includes management of the Clinical Research Review Committee (CRRC), which provides scientific review of all cancer related protocols. The CRRC approved protocol, consent and supporting documents are then submitted to IRB. Assistance with budget development and negotiation, as well as study account management is available. During conduct of the trial, Clinical Research Management (CRM) oncology certified nurse researchers and experienced data managers use a team approach to provide investigators with all aspects of study coordination. The CRM maintains a database of all institute clinical trials and is responsible for preparing NCI summary reports for current trial accrual. This includes tracking subject enrollment on all cancer related studies conducted through OHSU. For intervention studies enrollments need to be entered into the institute database within 3-5 days after consent signing or submitted to the CRM manager on the enrollment form listed under the Related Documents section. For studies that do not include an intervention or do not require consent, enrollment numbers are tracked on the annual continuing review. This includes gender, race and ethnicity. Continuous safety and accrual monitoring is provided the CRRC. The Data Safety and Monitoring Committee provides auditing for protocol compliance and adherence to IRB, NCI and FDA regulations.
Flow Cytometry Shared Resource
Director: Philip R. Streeter, PhD Operator: Mandy Boyd, BS
The Flow Cytometry Shared Resource (FCSR), which has operated as a core resource for institute members since 1996, provides advanced instrumentation, technical expertise, and technical services to meet the needs of institute members. The FCSR also provides training to institute members in data interpretation, experiment design, and routine operation, offering these investigators an additional cost-saving option of doing some of the work themselves. Finally, this resource saves valuable investigator time by analyzing specimens and preparing them, if needed.
FACS Calibur Analysis
FACS Analysis Training
*Costs per service hour are calculated with or without operator assistance
Gene Microarray Shared Resource
Director: Chris Harrington, PhD
The Gene Microarray Shared Resource (GMSR) operates as a full-service genemicroarray center that provides infrastructure and support for performing genearray experiments and managing and analyzing microarray data. Specifically, we provide institute members with: 1) expression profiling services using high-density oligonucleotide arrays; 2) advice and training on the use of microarrays and analysis of microarray data; and 3) support in producing and identifying high quality RNA samples for microarray analysis. A critical function of the Microarray core is to provide effective data warehousing and management capabilities that allow investigators to store, distribute and share genomic data. To meet this goal the GMSR works closely with the Cancer Institute Informatics Shared Resource in the development and ongoing support of a central microarray database and Web-based tools for project application, sample tracking, and data management. In addition to expression profiling services, the GMSR provides genotyping and CGH (comparativegenomehybridization) services using high density Affymetrix SNP arrays.
RNA quality assessment
Amplification and labeling o fRNA samples
Target/array processing–expression arrays
Data preparation/basic analysis. Online access to project data
Workshops, tutorials and support for data interpretation and analysis
Restriction digest, amplification and labeling of DNA samples
Target/array processing–SNP arrays
Data preparation/basic analysis
Workshops, tutorials and support for data interpretation and analysis – In development
Informatics Shared Resource
Director: Shannon McWeeney, PhD
The primary goal of the Informatics Shared Resource (ISR) is to provide informatics support and infrastructure to institute administration and other shared resources. In addition, the ISR will provide informatics consulting and user support to basic scientists, clinical researchers and population scientists who are conducting cancer research at OHSU.
Services and Resources
SUN SunFire V880 with four 900MHZ CPUs, 8GB memory, and 438GB local hard drives
Two SUN SunFire E3800s with four CPUs each at 900MHZ/8-MB cache and 4GB of memory
Two SUN SunFire v440 with four 1.062GHz CPUs each web-application/data servers with four 36GB hard disks and 8GB memory each
SUN Enterprise Server E450 with four 480MHz processors, 4GB memory, four 36GB internal drives with a 327GB SUN StorEdge T3WG RAID system
SUN Ultra 80 statistical server with two 360MHz processors and 1GB memory
Available application software includes Statistical Analysis System, R, Splus, MatLab 6.5, Oracle 8.1.7, Java, Perl, and others.
Informatics Seminar Series (co-hosted with the GCRC Informatics Core) [monthly]
Software Training and Workshops
ISR - CBCIBM ADCSR Joint Group Meetings (Staff Professional Development) [weekly]
Pathology Shared Resource
Director: Christopher Corless, MD, PhD
The Cancer Pathology Shared Resource is a core facility that provides tissue banking and related histology services to institute investigators. The facility collects and stores samples of normal and neoplastic human tissues from local hospitals. The nature and quality of all samples are verified by the director (a board-certified surgical pathologist) prior to their distribution. Relevant clinical and demographic data are provided with the tissue samples as needed. The facility also handles tissues from research animals and offers a full range of histology techniques for evaluating tissues of all types.
Histology: Including tissue processing and paraffin embedding, sectioning (cryostat or paraffin-embedded) to specified thickness, histochemical stains (including H&E, Trichrome, Elastin, Reticulin, Giemsa, Luxol fast blue, Iron, Bacterial/Fungal).
Laser Capture Microscopy: The laboratory has a PIXCELL II laser capture microscope (Arcturus Engineering) that can be used to microdissect small clusters of cells, or even single cells, for use in DNA, RNA or protein analyses. Cells can be dissected from either cryostat or paraffin sections that have been stained.
Immunohistochemistry: The laboratory has an automated Dako immunostainer with a capacity of 48 slides per run, supporting high-throughput staining. Services provided include: testing and titering new antibodies, both monoclonal and polyclonal, optimization of staining to enhance detection and reduce background, and double- and triple-antibody stains using multiple chromagens.
Tissue Procurement & Storage: A growing collection of normal and neoplastic human tissues is available to local investigators. The tissues are stored in several ways, each one optimal for a particular use.
Proteomics Shared Resource
Director: Larry David, DMD, PhD
This relatively new shared resource brings proteomic research techniques to bear on the cancer problem at OHSU. While proteomics has been largely associated with protein identification by mass spectrometry, the synergy of informatics tools and high-throughput analytical instrumentation has revealed new opportunities in biomarker discovery and systems biology, both of which will play a key role in future cancer research in the Institute. OHSU invested $1.9m in developing a campus wide proteomics unit, a unit that serves as the Proteomics Shared Resource (PSR) of the iInstitute. Under the direction of Dan Dorsa, OHSU Vice President for Research, a proteomics steering committee was created to assist Dr. David in further enhancing the use of the Proteomics Shared Research by the OHSU community. This committee, chaired by Dr. Peter Gillespie, is composed of six members who actively use mass spectrometry and proteomics in their research. A formalized cooperative agreement between the OHSU Proteomics Shared Resource and the proteomics cores at the University of Oregon and Oregon State University is in process to share instrumentation and expertise. This will greatly enhance the application of new proteomics technologies in cancer research at OHSU and the other major state universities in Oregon.
Economy protein ID by MALDI
Full service protein ID by MALDI
Full service protein ID by LC/MS/MS
MUDPIT or multidimensional protein identification
Mass determination of proteins or peptides (MALDI or ESI)
Robotic spot excision of gel plugs
Manual and automated sample preparation.
Additional services that will be offered in the next year include protein expression analysis and mapping of post-translational modifications.
Transgenic/Gene Targeting Shared Resource
Director: Lev Fedorov, PhD
The mission of the OHSU Transgenic/Gene Targeting Shared Resource is to assist investigators achieving research objectives that concern the production of genetically engineered mice and the management of the mouse colony size by cryopreservation of mouse germplasm. (Note: Originally, the goal was to simply freeze sperm as part of the cryopreservation laboratory, which was funded by the “Oregon Opportunity” funding Initiative. However, while setting up this laboratory, it became apparent that many PIs wanted to have trial data on reconstituting animals from frozen sperm. The laboratory is now set up for cryopreservation of both sperm and embryos, and to produce pre-implantation embryos for cryopreservation by IVF, similar to the model developed by the Jackson Laboratory termed “Speed Cryo” to rapidly cryopreserve large numbers of strains, particularly induced mutant mice that are held on the C57BL/6 inbred background.)
Gene Targeting in ES cells
Chimera Construction by Blastocyst Injection
Rederivation of SPF Strains
Lentiviral Vector-mediated Transgenic Mice
Cryopreservation of Mouse Germplasm